the aid library

LIST OPTIONS

Filter

2468

Sort by:

Direction:

Download (205)

View PDF (422)

Guidelines for screening for Tuberculosis infection and disease during the domestic medical examination for newly arrived refugees

U.S. Department of Human Services; Centers for Disease Control and Prevention; National Center for Emerging and Zoonotic Infectios Diseases (2012) C_CDC

Division of Global Migration and Quarantine April 16, 2012

Download (861)

View PDF (846)

Pedoman Tatalaksana Pencegahan Penyakit Kardiovaskular pada Perempuan

Lukito, A.A., A.U. Rahajoe, L.I. Rilantono, et al., Indonesian Heart Association (2015) C1

Guidelines for the Prevention of Cardiovascular Disease in Women in Indonesia

Download (1018)

View PDF (2511)

Framework towards tuberculosis elimination in low-incidence countries

World Health Organization (2014) C_WHO

This Framework offers a coherent approach for eliminating tuberculosis (TB) in low-incidence countries. It is designed to guide national policy-makers and those responsible for technical aspects of the national TB response in accelerating efforts towards elimination. The document will also be inform... more

Download (784)

View PDF (1669)

Questions and Answers About Tuberculosis
recommended

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, Centers for Disease Control and Prevention (2014) C_CDC

Download (1904)

View PDF (1880)

Deutsche und fremdsprachige Informationsmaterialien zur Gesundheit von Kindern und Jugendlichen

Landesinstitut für den Öffentlichen Gesundheitsdienst NRW (lögd) (2007) C1

Informationen zu Fragen der Prävention und Gesundheit ihrer Kinder und zu den Möglichkeiten der Sozialen Sicherung sind für Eltern von besonderer Bedeutung. Fremdsprachige Informationsmaterialien können die gegenseitige Verständigung und die Vermittlung von Informationen in der Beratung von... more

Download (393)

View PDF (2339)

Birth defects surveillance training: facilitator's guide

World Health Organization (WHO), National Center on Birth Defects and Developmental Disabilities from the United States Centers for Disease Control and Prevention (CDC), International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) (2015) C_WHO

The goal of this course is to provide participants with the foundational skills needed to begin the development, implementation and ongoing improvement of a congenital anomalies surveillance programme, in particular for countries with limited resources. It focuses on the methodology needed to devel... more

Download (3362)

View PDF (771)

Philippine Health Advisories

Department of Health, National Center for Health Promotion, National Center for Disease Prevention and Control (2012) C1

Download (167)

View PDF (312)

Addressing comorbidity between mental disorders and major noncommunicable diseases

World Health Organization WHO; Regional Office for Europe (2017) C_WHO

Reduced healthy life expectancy due to the high burden of both mental ill health and noncommunicable diseases (NCDs) is a major public health concern in the European Region. The links between mental disorders and major NCDs are well established. In clinical practice, however, mental disorders in pa... more

Download (118)

View PDF (152)

A situational analysis of programmatic management of TB preventive treatment in the WHO South-East Asia Region

World Health Organization WHO (2020) C_WHO

Tuberculosis (TB) prevention is essential for reaching the End TB targets in the South-East Asia Region (SEAR) of World Health Organization (WHO)1. The targets of 80% reduction in TB incidence rate and 90% reduction in TB mortality by 2030 (compared to 2015 levels) can be achieved only with addition... more

Download (75)

View PDF (124)

Framework for Fair, Equitable and Timely Allocation of COVID-19 Vaccines in Africa. Highlights Day 1

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C1

The virtual conference, co-organised by the Africa Centres for Disease Control and Prevention (Africa CDC) and the South African Medical Research Council (SAMRC) brought together African leaders, public health professionals and researchers, policymakers, business leaders and civil society and commun... more

Download (196)

View PDF (124)

Kenya national guidelines for cardiovascular diseases management. Handbook

Ministry of Health, Kenya (2018) CC

These guidelines for the prevention and management of cardiovascular diseases are a critical ingredient for streamlining care across the entire health services provision continuum. They are a strategic component in achieving universal health coverage, securing affordable heal... more

Download (206)

View PDF (294)

Keeping the 100-year-old promise: making insulin access universal

WHO (2021) C_WHO

High prices, hard-to-access human insulin, few insulin producers, and weak health systems are just some of the barriers that people with diabetes face a century after insulin was discovered, WHO notes in a new report

Download (64)

View PDF (613)

Flucht und Gesundheit: Allgemeine und aktuelle Hinweise (Ukraine)

Robert-Koch-Institut RKI (2022) C1

Gesundheitliche Belastungen Geflüchteter erfordern umfassende Präventionsangebote und Gesundheitsversorgung Im Allgemeinen ist die Gruppe Geflüchteter sehr heterogen, es bestehen allerdings besondere gesundheitliche Risiken. Daraus resultieren auch unterschiedliche Versorgungsbedarfe.

Download (89)

View PDF (109)

Estimación del Riesgo Cardiovascular

Ministerio de Salud Chile (2014) C2

Enfoque de riesgo para la prevención de enfermedades cardiovasculares, consenso 2014

Download (176)

View PDF (521)

National Guidelines for Diabetic Eye Care

Ministry of Health Malawi (2021) CC

Diabetes mellitus (DM) is a global epidemic with significant morbidity. Diabetic retinopathy (DR) is the specific microvascular complication of DM and affects 1 in 3 persons with DM. DR remains a leading cause of vision loss in working adult populations. Patients with severe levels of DR are report... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (20)

View PDF (26)

Global status report on noncommunicable diseases 2014 WHO

World Health Organization (WHO) World Health Organization (WHO) (2014) C_WHO

This global status report on prevention and control of NCDs (2014), is framed around the nine voluntary global targets. The report provides data on the current situation, identifying bottlenecks as well as opportunities and priority actions for attaining the targets. The 2010 baseline estimates on N... more

Download (11)

View PDF (13)

Toolkit for developing a multisectoral action plan for noncommunicable diseases: overview

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

This toolkit is a "how to" guide for developing, implementing and evaluating a multisectoral action plan for prevention and control of NCDs. It is targeted at policy-makers, planners and programme managers, and is intended to help countries, provinces and cities meet the requirements for achieving g... more

Download (17)

View PDF (26)

Toolkit for developing a multisectoral action plan for noncommunicable diseases: module 5: evaluating the implementation of a multisectoral action plan

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

Key stakeholders must be involved in the planning, implementation, monitoring and evaluation of NCD plans and programmes. Within a ministry of health there will be different types of stakeholders, such as programme managers and senior managers in departments of prevention, health promotion, and hosp... more

Download (17)

View PDF (17)

Toolkit for developing a multisectoral action plan for noncommunicable diseases: overview 2022

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

Questions and Answers About Tuberculosis recommended

Questions and Answers About Tuberculosis
recommended